Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis

References

• Gruenberg AM, Goldstein RD, Pincus HA. Classification of Depression: Research and Diagnostic Criteria: DSM-IV and ICD-10. Biology of Depression: From Novel Insights to Therapeutic Strategies. Wiley-VCH Verlag GmbH, 2008
   Google Scholar
• Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 2011;9:90
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD. Naghavi M. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96
   PubMed Web of Science ®Google Scholar
• O’Leary OFDT, Cryan JF. Faster, better, stronger: towards new antidepressant therapeutic strategies. Eur J Pharmacol 2015:32-50
   PubMed Web of Science ®Google Scholar
• Shelton RCOO, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs 2010;24:131-61
   PubMed Web of Science ®Google Scholar
• Rush AJTM, Wisniewski SR, Nierenberg AA, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Lehmann HE. Therapy-resistant depressions – a clinical classification. Pharmakopsychiatry 1974;7:156-63
   PubMed Web of Science ®Google Scholar
• Sartorius N. Description and classification of depressive disorder. Contributions for the definition of therapy-resistance and of therapy-resistant depressions. Pharmakopsychiatry 1974;7:76-9
   PubMed Web of Science ®Google Scholar
• Thase MERA. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997;58(Suppl 13):23-9
   Google Scholar
• Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums 2009;14:197-206
   PubMed Web of Science ®Google Scholar
• Souery DPG, Trivedi MH. Treatment-resistant depression. J Clin Psychiatry 2006;67(Suppl 6):16-22
   PubMed Web of Science ®Google Scholar
• Symbyax [package insert]. Indianapolis, IN: Eli Lilly and Company, 2009
   Google Scholar
• Cleare A, Pariante CM, Young AH. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015;29:459
   PubMed Web of Science ®Google Scholar
• Papakostas GISR, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007;68:826-31
   PubMed Web of Science ®Google Scholar
• Nelson JCPG. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psych 2009;166:980-91
   PubMed Web of Science ®Google Scholar
• Spielmans GIBM, Linardatos E, Rosenlicht NZ, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013;10:e1001403
   PubMed Web of Science ®Google Scholar
• Papakostas GINJ, Kasper S, Möller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2008;18:122-12
   PubMed Web of Science ®Google Scholar
• Bauer MDS. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999;19:421-34
   Web of Science ®Google Scholar
• Gaynes BNLS, Lux L, Gartlehner G, Hansen RA. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry 2014;75:477-89
   PubMed Web of Science ®Google Scholar
• Zhou XRA, Qin B, Del Giovane C, et al. Comparative efficacy, acceptability and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2014;76:487-98
   Web of Science ®Google Scholar
• Zhou XKG, Qin B, Ravindran A. Atypical antipychotics for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol 2015;18:1-10
   Web of Science ®Google Scholar
• Kirsch IMJ. Clinical trials and the response rate illusion. Contemp Clin Trials 2007;28:348-51
   PubMed Web of Science ®Google Scholar
• Zimmerman MPMCI. Derivation of a definition of remission on the Montgomery–Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatric Res 2004;38:577-82
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Cipriani A, Barbui C, et al. Imputing response rates from means and standard deviations in meta-analysis. Int Clin Psychopharmacol 2005;20:49-52
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58
   PubMed Web of Science ®Google Scholar
• The Cochrane Collaboration's for assessing risk of bias in randomised trials, BMJ 2011;343:d5928
   Google Scholar
• Lu G, Ades A. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24
   PubMed Web of Science ®Google Scholar
• Salanti G, Higgins JP,Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301
   PubMed Web of Science ®Google Scholar
• Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14:429-37
   PubMed Web of Science ®Google Scholar
• Jansen JP, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28
   PubMed Web of Science ®Google Scholar
• Cooper NJ, Sutton AJ, Morris D. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med 2009;28:1861-81
   PubMed Web of Science ®Google Scholar
• Jansen JP, Schmid CH, Salanti G. Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons. J Clin Epidemiol 2012;65:798-807
   PubMed Web of Science ®Google Scholar
• Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J Roy Stat Soc Series B Stat Meth 2002;64:583-639
   Web of Science ®Google Scholar
• Dias S, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607-17
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Ades AE, Welton NJ. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London, UK: National Institute for Health and Clinical Excellence, 2011
   Google Scholar
• Cope S,Zhang J, Stephen S, et al. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med 2014;12:93
   PubMed Web of Science ®Google Scholar
• Bauer M, Pretorius HW, Constant EL. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009;70:540-9
   PubMed Web of Science ®Google Scholar
• Berman RM, Marcus RN, Swanink R. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-53
   PubMed Web of Science ®Google Scholar
• Corya SAWD, Sanger TM, Briggs SD, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23:364-72
   PubMed Web of Science ®Google Scholar
• Dorée JP, Des Rosiers J, Lew V. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 2007;23:333-41
   PubMed Web of Science ®Google Scholar
• Fang Y, Yuan C, Xu Y. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. J Clin Psychopharmacol 2010;30:357-64
   PubMed Web of Science ®Google Scholar
• Fang YYC, Xu Y, Chen J, et al. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol 2011;31:638-42
   PubMed Web of Science ®Google Scholar
• Franco MMFMPP, Rihmer Z, Vavrusova L, et al. Quetiapine XR monotherapy and quetiapine XR + ongoing antidepressant versus lithium + ongoing AD for Stage II treatment-resistant major depressive disorder. Eur Neuropsychopharmacol 2010;20:S347
   Web of Science ®Google Scholar
• Li X, Xing B, Yu E. The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study. J Neuropsychiatry Clin Neurosci 2013;25:157-60
   PubMed Web of Science ®Google Scholar
• Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-65
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Papakostas G, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants J Clin Psychopahrmacol 2003;23:92-5
   PubMed Web of Science ®Google Scholar
• Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69:1228-336
   PubMed Web of Science ®Google Scholar
• Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Primary Care Companion to J Clin Psychiatry 2008;10:187-90
   PubMedGoogle Scholar
• Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol 2007;22:179-82
   PubMed Web of Science ®Google Scholar
• Shelton RCWD, Corya SA, Sanger TM, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005;66:1289-97
   PubMed Web of Science ®Google Scholar
• Singh J, et al. A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of intravenous ketamine in patients with treatment-resistant depression. Biol Psychiatry 2014;1:44S
   Google Scholar
• Thase ME, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007;68:224-36
   PubMed Web of Science ®Google Scholar
• Thase MEFMHM, Skuban A, Zhang P, et al. Efficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: a phase II randomized placebo-controlled study. ACNP 50th Annual Meeting 2011
   Google Scholar
• Bakim B, et al. The combination of antidepressant drug therapy and high-frequency repetitive transcranial magnetic stimulation in medication-resistant depression. Klinik Psikofarmakoloji Bulteni 2012;22:244-53
   Google Scholar
• Blumberger DM, Mulsant BH, Fitzgerald PB, et al. A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World J Biol Psychiatry 2012;13:423-35
   PubMed Web of Science ®Google Scholar
• Chen SJ, et al. Superior antidepressant effect occurring 1 month after rTMS: add-on rTMS for subjects with medication-resistant depression. Neuropsychiatric Dis Treat 2013;9:397-401
   PubMed Web of Science ®Google Scholar
• Fitzgerald PB, et al. A randomized trial of rTMS targeted with MRI based neuro-navigation in treatment-resistant depression. Neuropsychopharmacology 2009;34:1255-62
   PubMed Web of Science ®Google Scholar
• Fitzgerald PB, Hoya KE, Herringa SE, et al. A double blind randomized trial of unilateral left and bilateral prefrontal cortex transcranial magnetic stimulation in treatment resistant major depression. J Affect Disord 2012;139:193-8
   PubMed Web of Science ®Google Scholar
• Garcia-Toro M, Salva J, Daumal J, et al. High (20-Hz) and low (1-Hz) frequency transcranial magnetic stimulation as adjuvant treatment in medication-resistant depression. Psychiatry Res 2006;146:53-7
   PubMed Web of Science ®Google Scholar
• George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010;67:507-16
   PubMed Web of Science ®Google Scholar
• Pallanti SBS, Di Rollo A, Antonini S, Quercioli L. Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? Neuroscience 2010;167:323-8
   PubMed Web of Science ®Google Scholar
• Rosa MA, Gattaz WF, Pascual-Leone A, et al. Comparison of repetitive transcranial magnetic stimulation and electroconvulsive therapy in unipolar non-psychotic refractory depression: a randomized, single-blind study. Int J Neuropsychopharmacol 2006;9:667-76
   PubMed Web of Science ®Google Scholar
• Rossini D, Lucca A, Zanardi R, et al. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res 2005;137:1-10
   PubMed Web of Science ®Google Scholar
• Triggs WJRN, Ward HE, Cheng J, et al. Right and left dorsolateral pre-frontal rTMS treatment of refractory depression: a randomized, sham-controlled trial. Psychiatry Res 2010;178:467-474
   PubMed Web of Science ®Google Scholar
• Zhang XHWLW, Wang JJ, Liu Q, Fan Y. Adjunctive treatment with transcranial magnetic stimulation in treatment resistant depression: a randomized, boucle-blind, sham-controlled study. Shanghai Arch Psychiatry 2011;17-24
   Google Scholar
• Zheng H, Zhang L, Li L, et al. High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression. Progr Neuro Psychopharmacol Biol Psychiatry 2010;34:1189-95
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;163:1519-30; quiz 1665
   PubMed Web of Science ®Google Scholar
• McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive disorders. Psychol Med 2014;45:693-704
   PubMed Web of Science ®Google Scholar
• Janssen Research & Development. A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (SUSTAIN-2). clinicaltrials.gov : NCT02497287 October 2016
   Google Scholar
• Janssen Research & Development. A Long-term Safety Study of Intranasal Esketamine in Treatment-resistant Depression (SUSTAIN-3). clinicaltrials.gov : NCT027821042016
   Google Scholar
• Janssen Research & Development. A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (SUSTAIN-1). clinicaltrials.gov : NCT024938682016
   Google Scholar
• Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies with major depression: variable, substantial and growing. JAMA 2002;287:1840-7
   PubMed Web of Science ®Google Scholar